The company said that the Flo-Pred (prednisolone acetate oral suspension) brand, for which there are no generic equivalents, will be sold by prescription as an anti-inflammatory agent for the treatment of asthma, certain allergic and dermatologic conditions, as well as a variety of other indications.
The company plans to launch the product later in 2008 and market it through its TaroPharma Division of Taro USA.